Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations-Reference-Cited by-同舟云学术

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

Published:2024-01-24 Issue:3 Volume:67 Page:1734-1746
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Tyhonas John S.¹^ORCID,Arnold Lee D.¹,Cox Jason M.¹,Franovic Aleksandra¹,Gardiner Elisabeth¹,Grandinetti Kathryn¹,Kania Robert¹,Kanouni Toufike¹,Lardy Matthew¹,Li Chun¹,Martin Eric S.¹,Miller Nichol¹,Mohan Adithi¹,Murphy Eric A.¹,Perez Michelle¹,Soroceanu Liliana¹,Timple Noel¹,Uryu Sean¹,Womble Scott¹,Kaldor Stephen W.¹

Affiliation:

1. Kinnate Biopharma, San Diego, California 92130, United States

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01819

Reference12 articles.

1. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

2. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib

3. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

4. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

5. Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors;Cancer Research Communications;2024-04-30

2. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations;Clinical Cancer Research;2024-03-04

3. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions;Nature Reviews Clinical Oncology;2024-02-29